As its shareholders already know, CRISPR Therapeutics (NASDAQ: CRSP) has quite a few opportunities on the table. Between its commercialized medicine, a pipeline that's packed with chances to mint blockbuster drugs, and plenty of financial flexibility, there's no shortage of reasons to buy the stock.

But even for those who appreciate the company's merits, the picture is likely even sunnier than they realize. Here are three reasons why the stock is worth buying.

CRISPR's first commercialized product, a gene therapy called Casgevy, which treats or functionally cures both sickle cell disease (SCD) and beta thalassemia, is in the midst of its global rollout. Developed in partnership with Vertex Pharmaceuticals, Casgevy is now approved for sale in the U.S., E.U., and U.K., as well as several other countries. There are already 25 authorized treatment centers (ATCs) for administering the therapy operating worldwide, with many more slated to open over time.

Continue reading

Source Fool.com